Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › US Phase 2 (NCT06737042)

US Phase 2 (NCT06737042)

Bofanglutide (GZR18) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Bofanglutide (GZR18)
Population
obesity
Phase
2
Participants
326
Duration
36 weeks
Registry
NCT06737042

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
48 mg Q2W vs tirzepatide 15 mg QW (open-label active comparator): weight -16.93 %obesity36326——−15.2 %
estimand not specified
———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • 48 mg Q2W · weight_unsp · press release
    the 48 mg bofanglutide injection group achieved an average weight loss of 15.18%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: US Phase 2 (NCT06737042). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06737042/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.